Tag Archives: FiercePharmaAsia—TakedaCSL

FiercePharmaAsia—Takeda-CSL coronavirus tie-up; Qiming’s $1B VC fund; Fujifilm’s Avigan COVID-19 trial

Takeda has formed a multinational alliance to work on an unbranded hyperimmune globulin therapy for COVID-19. China’s Qiming Venture Partners, which previously backed CanSino Bio and Zai Lab, has set up another venture fund. Following some encouraging early evidence and the initiation of a Japanese study, Fujifilm will test influenza med Avigan in a U.S.… Read More »